Scientific Evidence
Clinical experience with a multiplexed immunofluorescence tissue biomarker assay (Tissue Cypher BE) in the management of Barrett’s esophagus: a single center experience
Jun 2018
Use of TissueCypher resulted in clinical “upstaging” occurred in 5 of 46 cases, leading to treatment that otherwise might not be pursued.
Publication: Poster presentation (Su1109) at DDW 2018, Washington DC
Systems biology approaches in cancer pathology
Jan 2018
A method for objective quantification of epithelial and stromal biomarkers to generate a tissue profile aiding predictive models for cancer pathology.
Publication: Methods in Molecular Biology
Signatures of field cancerization: a step towards earlier detection of esophageal adenocarcinoma
Aug 2017
Detection of the field effect in the clinical setting with validated, cost-effective diagnostic assays may increase the detection of HGD and EAC.
Publication: Translational Cancer Research
Signatures of field cancerization: a step towards earlier detection of esophageal adenocarcinoma
Aug 2017
Detection of the field effect in the clinical setting with validated, cost-effective diagnostic assays may increase the detection of HGD and EAC.
Publication: Translational Cancer Research
A tissue systems pathology test detects abnormalities associated with prevalent high-grade dysplasia and esophageal cancer in Barrett’s esophagus
Feb 2017
A tissue systems pathology test may provide an objective method to facilitate earlier therapeutic intervention of Barrett's esophagus patients.
Publication: Cancer Epidemiology, Biomarkers & Prevention
A tissue systems pathology assay for high-risk Barrett’s esophagus
Oct 2016
Exploration of a tissue systems pathology approach to predict progression in patients with non-dysplastic Barrett's esophagus.
Publication: Cancer Epidemiology, Biomarkers & Prevention
Individualized risk prediction in Barrett’s esophagus
Jul 2016
Barrett’s esophagus management decisions are often based on subjective diagnoses, so better information and techniques are needed to aid in BE patient care.
Publication: Medical Laboratory Observer
Individualized risk prediction in Barrett’s esophagus
Jul 2016
Barrett’s esophagus management decisions are often based on subjective diagnoses, so better information and techniques are needed to aid in BE patient care.
Publication: Medical Laboratory Observer
A tissue systems pathology assay for high-risk Barrett’s esophagus
May 2016
Exploration of a tissue systems pathology approach to predict progression in patients with non-dysplastic Barrett's esophagus.
Publication: Cancer Epidemiology, Biomarkers & Prevention
A tissue systems pathology test detects a field effect associated with high-grade dysplasia and esophageal cancer in Barrett’s esophagus patients
May 2016
TissueCypher better predicts the presence of HGD and EAC in BE than pathologic variables and can improve histology to identify patients requiring therapy.
Publication: Poster presentation (Sa1257) at DDW 2016, San Diego
A cost-effectiveness analysis of a test that predicts risk of malignant progression in Barrett’s esophagus
May 2016
TissueCypher is cost-saving after five years and improves patient outcomes due to improving the effectiveness of surveillance and treatment.
Publication: Podium presentation (CN4) at ISPOR 2016, Washington DC
A tissue systems pathology test detects a field effect associated with high grade dysplasia and esophageal cancer in Barrett’s esophagus patients
May 2016
TissueCypher better predicts presence of HGD and EAC in BE than pathologic variables, and can improve on histology to identify patients requiring therapy.
Publication: Poster presentation (Sa1257) at DDW 2016, San Diego